Abstract: Compositions and methods of treating a subject with cancer are described. The methods include administering to the subject a therapeutically effective amount of a pharmaceutical composition comprising a compound with the dual characteristics or restoring function of the c-Cbl ubiquitin ligase in cancer cells and in also worsening sublethal lysosomal dysfunction, preferably in combination with an agent capable of making cancer cells more oxidized. The pharmaceutical composition can be administered with an additional therapeutic agent or agents such as an agent that represents an accepted standard of care for the treatment of a particular type being treated. The methods can be used for treating a wide variety of different kinds of cancers, such as brain tumors, breast cancers, melanomas, breast cancers and lymphomas.

Abstract: There are provided methods, systems and processes for the utilization of microbial and related genetic information for use in the exploration, determination, production and recovery of natural resources, including energy sources, and the monitoring, control and analysis of processes and activities.

Abstract: Provided herein are compositions, kits and methods related to the treatment of one or more lysosomal storage diseases (LSDs) in a subject and methods of identifying agents that are useful for the treatment of one or more LSDs. The compositions, kits, and methods are based on the novel discovery that agents effective for treating LSD must have two characteristics: they must inhibit cell death and reduce suppression of cell division caused by toxic substances that accumulate in LSD. Exemplary agents include polypeptides (e.g., IGF-1, VEGF) and small molecules (e.g., chlorotrianisene, clofoctal, colforsin, and tulobuterol).